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ABSTRACT 
BACKGROUND AND PURPOSE: In 30-40% of hypertrophic cardiomyopathy (HCM) patients, 
symptomatic left-ventricular (LV) outflow gradients develop only during exercise due to 
catecholamine-induced LV-hypercontractility (inducible obstruction). Negative-inotropic 
pharmacological options are limited to β-blockers or disopyramide, with scarce efficacy and 
tolerability.  
We assessed the potential use of late Na+-current (INaL)-inhibitors to treat inducible obstruction in 
HCM.  
EXPERIMENTAL APPROACH: The electrophysiological and mechanical responses to β-adrenergic 
stimulation were studied in human myocardium from HCM versus control patients. We then 
investigated the effects of INaL-inhibitors (ranolazine and GS-967) in HCM samples under conditions 
simulating rest and exercise.  
KEY RESULTS: In cardiomyocytes and trabeculae from 18 surgical septal samples of patients with 
obstruction, the selective INaL-inhibitor GS-967 (0.5μM) hastened twitch kinetics, decreased diastolic 
[Ca2+] and shortened action potentials, matching the effects of ranolazine at a 20-times lower 
concentration.  
The mechanical response to isoproterenol (inotropic and lusitropic) was comparable in HCM and 
control myocardium. However, isoproterenol prolonged action potentials in HCM myocardium, while 
it shortened them in controls.  
At variance with disopyramide, neither GS-967 nor ranolazine reduced force at rest; however, in the 
presence of isoproterenol, they reduced Ca2+-transient amplitude and twitch tension, while the 
acceleration of relaxation was maintained. INaL-inhibitors were more effective than disopyramide in 
reducing contractility during exercise. Finally, INaL-inhibitors abolished arrhythmias induced by 
isoproterenol.  
CONCLUSIONS AND IMPLICATIONS:  Ranolazine and GS-967 are effective in reducing septal 
myocardium tension during simulated exercise in vitro and therefore have the potential to ameliorate 
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symptoms caused by inducible obstruction in HCM patients, with some advantages over disopyramide 
and β-blockers. 
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Symptoms related to obstruction occurring at the left ventricular outflow tract (LVOT) are 
present in approximately 65% of hypertrophic cardiomyopathy (HCM) patients (Gersh et al., 2011; 
Authors/Task Force et al., 2014). Marked upper septal hypertrophy and LV hypercontractility lead to 
accelerated blood flow in the LVOT, exerting a drag-force on the elongated anterior mitral valve 
leaflet that moves towards the septum (SAM), ultimately determining a significant pressure gradient 
(>30mmHg) in the LVOT (Maron et al., 2006).  While a significant gradient is present at rest in about 
half of patients with obstructive HCM , in obstruction develops only during stress or exercise in the 
other 50% (“dynamic” or “inducible” obstruction) (Maron et al., 2006; Pozios et al., 2015).  
To date, pharmacological options to treat inducible obstruction are limited to beta-blockers or 
disopyramide. High doses of non-selective β-blockers, such as 80-100 mg/day of nadolol, are ofter 
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required to reduce dynamic gradients (Nistri et al., 2012): a large number of patients with exertional 
symptoms do not tolerate such aggressive β-blocker treatments and are left with residual symptomatic 
gradients. Disopyramide (Dis) is an unselective compound that primarily behaves as a Na+-channel 
and hERG K+ channel blocker and is extensively used in HCM patients with rest obstruction to relieve 
symptoms associated with LVOT gradients or intraventricular gradients. The clinical efficacy of Dis 
on rest obstruction has been attributed to its negative inotropic effect: through the reduction of LV 
contractility, Dis slows down the acceleration of flow in the LVOT during systole, thus delaying or 
abolishing mitral-septal contact (Sherrid et al., 2005). However, the use of Dis for inducible 
obstruction is limited by its unpredictable efficacy on dynamic gradients, particularly those elicited by 
exercise (Maron et al., 2006); and by the important side effects of the drug (e.g. the anticholinergic 
effects). Thus, there is a strongly felt need to identify more effective and better tolerated agents for 
patients with obstructive HCM. However, the identification of new pharmacological options to reduce 
dynamic gradients is limited by the lack of studies on the cellular pathophysiology of exercise-
induced obstruction. In particular, the response to β-adrenergic stimulation has never been studied in 
human myocardium from HCM patients. 
We previously analyzed the electromechanical profile of cardiomyocytes isolated from 
myectomy samples of patients with obstructive HCM (Coppini et al., 2013). When compared with 
control cells, HCM cardiomyocytes showed prolonged action potentials (APs), slower Ca2+-transients 
and elevated diastolic Ca2+, largely determined by a marked overexpression of the late Na+ current 
(INaL). Such electro-mechanical abnormalities were reversed in vitro by the INaL inhibitor ranolazine, 
with beneficial effects on diastolic function and cellular arrhythmias (Coppini et al., 2013). 
Ranolazine is available in the clinic to treat stable angina and is being employed in HCM patients with 
angina symptoms(Ammirati et al., 2016). However, Ranolazine is a non-selective INaL-inhibitor, with 
several potentially relevant pleiotropic effects, such as the inhibition of K+ and Ca2+ currents 
(Antzelevitch et al., 2004), the reduction of myofilament Ca2+-sensitivity (Lovelock et al., 2012) and 
the stabilization of ryanodine receptors (Parikh et al., 2012). Novel, highly selective INaL inhibitors 
(GS-967 and GS-6615) (Belardinelli et al., 2013; Rajamani et al., 2016) have been recently 
developed. GS-967 (6-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-
  
This article is protected by copyright. All rights reserved. 
a]pyridine) is a potent inhibitor of INaL(Belardinelli et al., 2013), with an IC50 of 0.2 to 0.5 µM (IC50 
of ranolazine is 2-4 µM ). Moreover, GS-967 has no significant effects on either peak INa or hERG K+ 
current in the effective range of concentrations (Belardinelli et al., 2013). GS-967 has been shown to 
suppress experimentally-induced ventricular arrhythmias in rat and rabbit cardiomyocytes, via 
shortening of AP duration and reduction of intracellular Na+ and Ca2+ overload (Belardinelli et al., 
2013; Sicouri et al., 2013; Pezhouman et al., 2014); this in turn abolished the occurrence of 
arrhythmogenic early and delayed after-depolarizations (EADs and DADs) (Belardinelli et al., 2013; 
Sicouri et al., 2013; Pezhouman et al., 2014). Moreover, GS-967, used in living porcine models, 
suppressed ischemia-induced and catecholamine-triggered ventricular arrhythmias (Bonatti et al., 
2014; Alves Bento et al., 2015), as well as atrial fibrillation triggered by autonomous stimulation 
(Carneiro et al., 2015). Notably, GS-967 did not exert any effects on the mechanical and electrical 
function of the rat healthy heart (Fernandes et al., 2014). This result is in line with the negligible 
effects of ranolazine in human myocardium from non-hypertrophic non-failing patients (Coppini et 
al., 2013), due to the absence of INaL overexpression, which appears to be a specific, disease-related, 
target. 
In the present study we first use GS-967 as a pharmacological tool to assess whether the 
previously observed effects of ranolazine in human HCM myocardium can be entirely attributed to 
INaL-inhibition rather than its pleiotropic effects. We then compare the mechanical and 
electrophysiological responses of HCM myocardium to β-adrenergic agonist isoproterenol with those 
observed in control cardiac samples, in order to characterize the features and possible abnormalities of 
β-adrenergic signaling in the HCM heart. Finally, the main objective of this study is to investigate the 
in vitro effects of ranolazine and GS-967 under β-adrenergic stimulation, the latter used to simulate 
stress and exercise in the myocardium of patients with obstructive HCM. With this approach, we aim 
to assess whether the in vitro pharmacological profile of INaL-inhibitors supports their use to treat 
inducible obstruction in HCM patients as an alternative to disopyramide and β-blockers or in 
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METHODS 
Details are available online (“Expanded Methods” section of the Online Data Supplement). 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2017/18 (Alexander et al., 2017). 
Patients: The study follows the principles of WMA Declaration of Helsinky for medical 
research involving human subjects.  The experimental protocols were approved by the ethical 
committee of Careggi University-Hospital of Florence (2006/0024713, renewed May 2009; 
2013/0035305).  Each enrolled patient gave written informed consent. We enrolled 22 HCM patients 
followed by the Cardiomyopathy Unit in Florence, consecutively referred to surgical septal 
myectomy, for relief of drug-refractory symptoms related to LVOT obstruction. Among the 22 
patients, 15 agreed to undergo mutational screening in sarcomeric genes. Clinical data are found in 
Table 1.  
The control cohort comprised 5 patients aged <65 years undergoing heart surgery for aortic 
stenosis or regurgitation and who required a septal myectomy operation due to the presence of a 
bulging septum causing symptomatic obstruction. All control patients had septal thickness <14mm 
and preserved left-ventricular systolic function (ejection fraction >55%). Clinical data are found in 
Supplementary Table 1.    
Tissue processing and cell isolation: Surgical septal specimens from HCM and control 
patients were washed with standard cardioplegic solution and processed within 30 minutes from 
excision. Endocardial trabeculae suitable for mechanical measurements were dissected and the 
remaining tissue was minced and subjected to enzymatic dissociation to obtain viable single 
myocytes, as previously described (Coppini et al., 2014a). 
Single cell studies: Perforated patch whole-cell current-clamp was used to measure 
membrane potential, as previously described (Coppini et al., 2013). [Ca2+] variations were 
simultaneously monitored using the Ca2+-sensitive fluorescent dye Fluoforte (Enzo Life Sciences, 
Farmingdale, NY), by measuring fluorescence at 515±10 nm during excitation at 490±8 nm. Cells 
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were mechanically permeabilized at the end of the experiment and free intracellular Ca2+ 
concentration ([Ca2+]i) was calculated from emitted fluorescence as previously described (Voigt et al., 
2012), using 389 nmol/L as Fluoforte dissociation constant. Late Na+ current and L-Type Ca2+ current 
(ICaL) were measured using whole-cell voltage clamp as previously described (Coppini et al., 2013). 
ICaL was also recorded under action potential clamp conditions, using representative AP traces, 
recorded from HCM cardiomyocytes under the same conditions, as command voltage. The inward 
current recorded under AP-clamp conditions was dihydropiridine-sensitive (see Supplementary Figure 
6)   
Intact trabeculae studies: Ventricular trabeculae were mounted between a force transducer 
and a motor for muscle length control, as previously described (Coppini et al., 2013); isometric force 
was recorded under different experimental conditions and stimulation protocols. Isometric force was 
recorded at 35±2°C under various conditions including various pacing rates (0.1-2.5 Hz) and acute 
drugs administration (see below). The occurrence of premature beats was evaluated during steady 
state stimulation (0.5 Hz) and during stimulation pauses. 
Drug studies: For experiments on isolated cardiomyocytes and trabeculae Ran was used at 
the concentration of 10 µM, Dis at 5 µM and GS-967 at 0.5 µM, unless otherwise specified. Each cell 
or trabecula was randomly assigned to be treated with one of the three test drugs (Dis, Ran or GS-
967). Test recordings in presence of the drug were performed after >3 minutes from the beginning of 
drug exposure. Afterwards, the drug was washed out for >5 minutes and measurements were repeated. 
Isoproterenol (10-7 M) was used to mimic β-adrenergic stimulation during exercise in single cells and 
trabeculae.  
Statistics: Raw traces were analysed by a blinded operator, different from the one who 
performed the experiments. For each trace, we performed measurements in at least 5 subsequent 
events and averaged them to obtain a single value for a given cell/trabecula in a certain condition. 
Clinical data from patients are expressed as mean±SD. Data from cells and muscles are expressed as 
mean±SEM. Figure panels 1G, 2D and 2F show the effects of drugs in a normalized fashion: we 
calculated the drug-induced variation of a given parameter from the baseline ([drug-
baseline]/baseline, expressed as percentage) in each cell/trabecula and used these values (percentages 
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of variation) to calculate averages and perform statistical analyses. The number of cells/trabeculae and 
the number of different patient samples from which cells/trabeculae were isolated are indicated for 
each group/condition in the respective figure legends. For each group, we included data points from at 
least 5 patient samples, obtained from an even number of cells/trabeculae for each sample. Statistical 
analysis was performed as previously described using linear mixed models (Coppini et al., 2013), 
taking into account non-Gaussian distribution, inequality of variances and within-subject correlation. 
In brief, in order to reduce the risk of type I errors resulting from the closer interrelationship between 
cells/trabeculae isolated from the same patient sample, we used hierarchical statistics including two 
nested levels (patients and cells)(Sikkel et al., 2017); a third hierarchical level was added when drugs 
were tested in a cell/trabecula, in order to allow paired comparisons. This approach was implemented 
using linear mixed models in Stata 12.0 (StataCorp LLC, USA). For categorical data (e.g. occurrence 
of cellular arrhythmias), we used the Fisher exact test. P<0.05 was considered statistically significant. 
Due to poor availability of control samples, the number of control cells/trabeculae included in the 
unpaired comparisons (Fig.2) is lower than that of HCM cells/trabeculae.     
 
RESULTS 
GS-967 shortens action potentials and accelerates the kinetics of Ca2+ transients and 
twitches in HCM cardiomyocytes.  
GS-967 was tested at 0.5 µM in isolated cardiomyocytes from HCM patients during patch-
clamp and Ca2+-fluorescence measurements (Fig 1A). GS-967 consistently reduced INaL by 66±8% on 
average (Fig 1A). Moreover, GS-967 shortened the duration of action potentials at all frequencies 
studied (Fig. 1B-C). Average reduction of APD90% was 23.3±7.4 % at 0.2 Hz, 22.3±6.2 at 0.5Hz and 
21.4±6.7 % at 1 Hz. Moreover, GS-967 reduced the rate of arrhythmogenic early-afterdepolarizations 
(EADs) occurring spontaneously during regular stimulation for 3 minutes. The number of cells 
showing EADs during 3 minutes of stimulation was halved by GS-967 (Supplementary Fig. 2). 
Notably, GS-967 had no effects on the upstroke time nor on the amplitude of the action potentials 
(Supplementary Table 3). The kinetics of intracellular Ca2+ transients was hastened by GS-967 at all 
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frequencies investigated (Fig. 1D-E): both the rise and decay times of Ca2+ transients were shortened 
by GS-967 application (Supplementary Table 3). GS-967 reduced diastolic [Ca2+], while the 
amplitude of Ca2+ transients was unaffected (Fig. 2F-G). Accordingly, GS-967 reduced the occurrence 
of delayed after-depolarisations (Supplementary Fig. 2). GS-967 was then tested in intact trabeculae 
from HCM patients, while recording force under isometric conditions (Fig. 2H) during stimulation at 
different frequencies (0.1 Hz to 3 Hz). GS-967 shortened twitch duration mainly by reducing time to 
peak contraction (Fig. 2J). GS-967 (0.5µM) had no effects on action potentials and Ca2+ transients 
recorded from cardiomyocytes isolated from control patients (Supplementary Figure 3).   
 
Β-adrenergic stimulation exerts comparable mechanical effects in HCM and control 
myocardium, but causes a paradoxical prolongation of action potentials in HCM 
cardiomyocytes. 
 The effects of β-adrenergic stimulation with isoproterenol (10-7 M, Iso) on isometric twitches 
were tested in trabeculae from control and HCM septal samples (Fig. 2 A-D). Iso exerted qualitatively 
and quantitatively similar effects on twitch amplitude and kinetics in control and HCM trabeculae. In 
particular, Iso increased peak force by 3.4±0.6 times in control and 3.2±0.5 times in HCM trabeculae 
(Fig. 2 B). Twitch kinetics was slower in HCM vs. control trabeculae both at baseline and under β-
adrenergic stimulation (Fig. 2 C). Indeed, Iso accelerated the kinetics of relaxation by a similar 
amount in HCM and control trabeculae; however, the acceleration of twitch force development was 
less pronounced in HCM trabeculae (Fig. 2 D). All in all, the kinetics of contraction and relaxation, 
despite being accelerated by isoproterenol, was still slower in HCM vs. control trabeculae even during 
maximal β-adrenergic stimulation. 
 Contrarily, the effects of Iso on action potentials were profoundly different in HCM with 
respect to control cardiomyocytes (Fig. 2 E). While Iso shortened the duration of action potentials in 
control cardiomyocytes, β-adrenergic stimulation prolonged repolarization in all cardiomyocytes from 
HCM patients (Fig. 2 F). 
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Ranolazine and GS-967 decrease isometric force under β-adrenergic stimulation.  
We tested the effects of Dis (5 µM), Ran (10 µM), GS-967 (0.5 µM) and propranolol (0.1 
μM) on isometric twitch amplitude and kinetics in trabeculae from HCM patient samples, in the 
absence and presence of β-adrenergic stimulation with isoproterenol (10-7 M, Iso), used to simulate 
exercise or stress conditions.  Under baseline conditions, Dis reduced twitch amplitude by 
approximately 50%, while force was unaffected by Ran, GS-967 and propranolol (Fig.3A&C). β-
adrenergic activation with Iso led to the expected increase of twitch amplitude and hastening of twitch 
kinetics (Fig. 3A,B,D). Interestingly, Dis, Ran, GS-967 and propranolol reduced twitch amplitude 
when applied on top of isoproterenol (Fig. 3A-C). The reduction of twitch amplitude under Iso was 
quantitatively less pronounced with Dis (-16±7%) as compared with Ran (-56±23%, P< 0.01 vs. Dis) 
or GS-967 (-32±21%, P< 0.05 vs. Dis; see Fig. 3A&C). The reduction of twitch force in the presence 
of Ran or GS-967 was comparable with that obtained by blocking β-adrenergic receptors with 
propranolol (Fig.3C). Nonetheless, the acceleration of twitch kinetics by Iso was not antagonized by 
the application of Dis, Ran or GS-967 (Fig. 3A,B,D). Indeed, after the addition of these drugs on top 
of Iso, both time to peak and 50% relaxation time remained as fast as in the presence of Iso alone 
(Fig.3D). Contrarily, propranolol completely antagonized the lusitropic effect of isoproterenol 
(Fig.3D).  
 
Cellular mechanisms underlying the effects of INaL-inhibitors under isoproterenol.  
 
Ran and GS-967 were similarly tested in isolated HCM cardiomyocytes (Fig.4, Table 2). In 
line with the effects observed on twitch amplitude in trabeculae, Ran and GS-967 did not affect Ca2+ 
transient amplitude at baseline (Fig.4A). Ca2+ transient amplitude increased in response to Iso by 
14±3%. The application of either Ran or GS-967 on top of Iso significantly reduced Ca2+ transient 
amplitude (Fig. 4B). Interestingly, while Iso did not affect intracellular diastolic [Ca2+], Ran and GS-
967, applied on top of Iso, significantly reduced diastolic [Ca2+] (Fig. 4C). Interestingly, Iso 
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accelerated Ca2+-transient decay but prolonged Ca2+-transient rise time in HCM cardiomyocytes (Fig. 
4A, Table 2). Accordingly, Iso slowed time-to-peak shortening in HCM cardiomyocytes, but 
accelerated relaxation (Supplementary Fig.1).  Ran and GS-967 shortened Ca2+ transient rise when 
applied on top of β-adrenergic stimulation with Iso, but did not affect Ca2+ transient decay kinetics 
(Fig. 4A, Table 2). In line with that, Ran and GS-967 reverted the prolongation of action potentials 
induced by Iso (Fig 4 A&D). Contrarily, ranolazine (on top of isoproterenol) did not affect the 
duration of APs in control myocytes (Supplementary Figure 4A-B); in line with that, GS-967 did not 
reduce twitch force during β-adrenergic stimulation in control trabeculae (Supplementary Figure 4C-
D). We excluded that the reduction of Ca2+ transients and force by INaL-inhibitors under β-stimulation 
depends on a partial block of β-adrenergic receptors by these compounds (Supplementary Figure 5): 
binding studies showed that ranolazine has a very mild interaction with β1 and β2 receptors at the 
concentration used in this work (10µM), while GS-967 does not bind β-receptors, even at very high 
concentrations. In further support of this hypothesis, we found that ranolazine exerted a negative 
inotropic effect also when the positive inotropic effect of β-adrenergic stimulation was mimicked by 
forskolin, thereby bypassing the β-receptors (Supplementary Figure 4E-F). Finally, we investigated 
whether inhibition of L-Type Ca2+ current by INaL-inhibitors contributed to the observed effects (Fig. 
5). We found that neither ranolazine nor GS-967 affect the peak density of ICaL in HCM 
cardiomyocytes (Fig. 5A-B). Interestingly, we noticed that isoproterenol not only increases the 
amplitude of ICaL, but also markedly slows down current’s inactivation in HCM cells (Fig. 5C-D). 
Using the AP-clamp technique, we found that the prolongation of action potential by Iso increases the 
total inward flow of Ca2+ during the plateau of the AP (Fig.5E-F): this is mainly determined by the 
direct effects of β-stimulation on ICaL (i.e.the increased ICaL amplitude and prolonged inactivation) 
rather than being a consequence of AP prolongation (Supplementary Fig.6). Ranolazine,added on top 
of Iso, markedly reduces the total inward flow of Ca2+ in HCM myocytes (Fig. 5E-F): this is a 
consequence of the marked shortening of action potentials caused by INaL inhibition under β-
adrenergic stimulation (Supplementary Fig.6). 
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INaL-inhibitors abolish cathecolamine-induced arrhythmia in HCM myocardium. 
 
We then evaluated the effects of Ran and GS-967 on cellular arrhythmias evoked by β-
adrenergic stimulation (Fig.6A-B). Iso markedly increase the occurrence of both early and delayed 
after-depolarisations in HCM cardiomyocytes (Fig.6). Interestingly, both Ran (10µM) and GS-967 
(0.5 µM) reduced the occurrence of EADs and DADs. 
Finally, we evaluated the frequency of premature spontaneous beats and sustained triggered 
activity occurring in HCM trabeculae during stimulation pauses in the presence of Iso (Fig. 7 A&B). 
When added on top of Iso, Ran and GS-967 markedly reduced the occurrence of arrhythmic events 




Selective INaL inhibition: a disease-specific pharmacological option for HCM treatment 
INaL is three times larger in the myocardium of HCM patients compared to that of non-failing 
non-hypertrophic subjects, leading to a prolonged action potential duration that we observed 
consistently in myocardial samples from over 30 HCM myectomy patients (Coppini et al., 2013). In 
our view, these results highlight INaL inhibition as a disease-specific pharmacological strategy to treat 
HCM. We previously confirmed this hypothesis by acutely applying ranolazine on myocardial 
samples form myectomy HCM patients, where we observed marked beneficial effects on diastolic 
function and arrhythmogeneicity (Coppini et al., 2013). In this work, a novel, more selective INaL 
inhibitor, GS-967, was tested in intact cardiomyocytes and trabeculae from 18 HCM patients, in order 
to confirm that the beneficial effects previously observed with ranolazine (Coppini et al., 2013) were 
indeed consequence of INaL inhibition and were not mediated by the other pleiotropic effects of the 
drug (such as inhibition of K+ and Ca2+ currents (Antzelevitch et al., 2004), reduction of myofilament 
Ca2+-sensitivity (Lovelock et al., 2012), stabilization of ryanodine receptors (Parikh et al., 2012) or a 
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mild beta-blocker effect (Flenner et al., 2016)).  Here, we found that all the effects of GS-967 
observed in HCM myocardium are qualitatively and quantitatively similar to those previously 
obtained with ranolazine, but they are achieved at a 20-times lower concentration (0.5μM GS-967 vs. 
10μM ranolazine), owing to the increased potency and selectivity for INaL. As an example, 0.5μM GS-
967 reduced  INaL in HCM myocytes by 67% (Fig.1), while ranolazine inhibited 72% of INaL at 10μM 
(Coppini et al., 2013). Moreover, GS-967, just like ranolazine, shortened AP duration, reduced the 
risk of arrhythmogenic EADs (Fig.1), lowered diastolic [Ca2+], suppressed the risk of DADs, 
accelerated Ca2+ transient kinetics and hastened twitch relaxation in HCM myocardium (Fig.1). All in 
all, our results indicate that GS-967 may exert the same possible beneficial effects as ranolazine on 
arrhythmias and diastolic function,  the main determinants of symptoms and outcome in HCM 
patients (Coppini et al., 2014b; Olivotto et al., 2015).   
These results also have important mechanistic implications. Since GS-967 does not affect any 
other relevant target besides INaL at this concentration  (Belardinelli et al., 2013), our results confirms 
that the reduction of arrhythmogeneicity and the amelioration of diastolic function, previously 
observed with ranolazine (Coppini et al., 2013), are a direct consequence of INaL inhibition. Of note, 
we observed no major effects of GS-967 in cardiomyocytes from control patients (Supplementary Fig. 
3), as previously observed with ranolazine (Coppini et al., 2013), suggesting that the efficacy of INaL 
inhibitors is specific to disease conditions where a pathological increase of INaL is observed.  
In addition to the acute effects on myocardial function, INaL-inhibition may lead to additional 
benefits during long-term treatment. Work from our group showed that lifelong INaL inhibition in a 
mouse model of HCM prevents the development of hypertrophic phenotype and LV 
dysfunction(Coppini et al., 2017) and suggest that INaL inhibition with ranolazine or more selective 
agents may be an effective disease-modifying strategy in patients with HCM.  
 
INaL inhibitors: novel options to treat inducible obstruction? 
The principal aim of this work is to investigate the potential of INaL inhibitors in HCM further from the 
two previously evidenced rationales, i.e. reduction of the arrhythmic risk and the amelioration of 
symptoms related to diastolic dysfunction. Here we tested these compounds as negative-inotropic 
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agents to decrease exercise-induced LV septal hypercontractility, which is considered a direct cause 
of obstruction-related symptoms in patients with obstructive HCM. 
The negative-inotropic agents that are currently used to treat obstructive HCM are limited, 
particularly for the cases of inducible obstruction. Despite its widespread use, disopyramide is far 
from being the perfect drug to control obstructive symptoms: it has been successfully employed for 
more than 40 years to treat rest obstruction but has a very limited efficacy on exercise-induced LVOT 
gradients (Maron et al., 2006). In addition, anticholinergic undesired effects (mouth dryness, 
constipation, drowsiness) are relatively common and may require discontinuation of the drug unless 
they may be controlled by pyridostigmine (Sherrid, 2016). β-blockers, the only available therapeutic 
option to treat inducible obstruction, are often insufficient to control symptoms, and the high dosages 
required to significantly impact on dynamic LVOT gradients may be poorly tolerated (Nistri et al., 
2012). 
Our results show that selective INaL-inhibitors reduce myocardial force only during intense β-
adrenergic stimulation, mimicking stress or exercise, while leaving baseline (“rest”) contractility 
unaffected. Interestingly, the lusitropic effect of β-adrenergic stimulation (i.e. acceleration of 
relaxation) is maintained, while only the positive inotropic effect is lost. This is at variance with β-
blockers which, by acting at receptor level, antagonize the full spectrum of β-adrenergic effects, 
including the acceleration of relaxation (Fig.3) and the increase in heart rate, both essential for 
tolerating intense exercise activity. Interestingly, this effect appears to be specific of HCM 
myocardium, as the reduction of contractile force by INaL inhibitors during adrenergic stimulation is 
not observed in myocardial samples from control patients (Supplementary Fig. 4). The cellular 
mechanisms underlying the unexpected negative inotropic action of INaL inhibitors under β-adrenergic 
stimulation in HCM myocardium have been extensively investigated. 
 
Mechanisms underlying the negative-inotropic action of INaL-inhibitors under β-
adrenergic stimulation in HCM myocardium. 
1)Altered electrical response to β-adrenergic stimulation in HCM myocardium  
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By directly comparing the response of HCM myocardium to β-adrenergic stimulation with 
that of control cardiac muscle (Fig. 2), we here provided the first characterization of the features and 
abnormalities of β-adrenergic signaling in human hearts from HCM patients. In particular, we 
observed that the mechanical response to isoproterenol in terms of increased force amplitude and 
relaxation velocity was comparable in HCM and control trabeculae, but contractile kinetics remains 
slower in HCM vs. control trabeculae, even during maximal β-adrenergic stimulation. These results 
indicate that the subcellular mechanisms responsible for the lusitropic effects of β-adrenergic cascade 
are essentially preserved in HCM myocardium: HCM myofilaments retain the ability to decrease 
Ca2+-sensitivity upon phosphorylation of troponin-I by PKA (Sequeira et al., 2013), and PKA-
mediated phosphorylation of phospholamban occurs normally in human HCM myocardium (Coppini 
et al., 2013; Helms et al., 2016). 
On the contrary, the electrophysiological response to isoproterenol in isolated HCM 
cardiomyocytes was profoundly abnormal (Fig 2E-F). Among the many different effects on 
sarcolemmal and SR targets, Iso enhances both L-Type Ca2+ current and the slow delayed rectifier K+ 
current (IKs), with the latter prevailing in healthy human cells (Terrenoire et al., 2005), thus leading to 
a net reduction of the APD (Taggart et al., 2003) in control myocardium (Fig. 2E-F).  In HCM 
cardiomyocytes, hypertrophic remodeling leads to the unbalanced changes in the expression of Ca2+ 
and K+ currents (Coppini et al., 2013), that is, the expression of all K+ channels (including those 
responsible for IKs) is greatly reduced in the presence of a normal (or even slightly increased) density 
of ICaL, as compared with control myocardium.  In HCM myocytes, in response to  β-stimulation, the 
potentiation of ICaL prevails over the increase of K+ currents, thus leading to a net increase of 
depolarizing currents during the plateau of the AP,  causing the observed  “paradoxical” prolongation 
of APD (Fig. 2E-F). Moreover, in HCM cardiomyocytes, β-adrenergic stimulation not only increases 
peak ICaL amplitude, but also markedly slows down ICaL inactivation (Fig. 5). The marked slowing of 
ICaL inactivation is likely to contribute to the prolongation of APs by β-adrenergic stimulation. 
Additionally, it was previously shown that beta-adrenergic stimulation of ventricular cardiomyocytes 
with isoproterenol leads to INaL enhancement (Dybkova et al., 2014) through activation of CaMKII. A 
further increase of INaL following β-adrenergic stimulation in HCM myocytes may have contributed to 
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the paradoxical prolongation of APs observed in these cells. This paradoxical response might be 
relevant for the pathophysiology of exercise or stress-induced arrhythmias in HCM patients, as AP 
prolongation increased the risk of arrhythmogenic early-afterdepolarizations and triggered activity in 
HCM myocardium (Fig. 5 and 6). 
 
2)Altered calcium response to β-adrenergic stimulation in HCM myocardium  
In HCM cardiomyocytes, unlike control myocardium, the β-adrenergic-dependent increase of 
Ca2+ release and force may greatly rely on the increase in the duration of Ca2+ entry via L-Type Ca2+ 
channels caused by by the slower ICaL inactivation). In addition to the enhancement of ICaL, increased 
Ca2+-entry via reverse-mode NCX contributes to augment Ca2+-transients upon β-stimulation 
(Perchenet et al., 2000);  the latter is likely to be a consequence of the elevation of intracellular [Na+] 
in response to the enhancement of INaL and the prolongation of AP plateau that follows β-adrenergic 
stimulation (Dybkova et al., 2014) (Coppini et al., 2013). Indeed, we found that the rise time of Ca2+ 
transients prolongs in response to Iso in HCM cardiomyocytes (Fig. 4, Table 2). The prolongation of 
Ca2+-transient rise time may have direct mechanical consequences: indeed, we observed that the 
acceleration of twitches’ rising phase (time to peak) upon β-stimulation was significantly less 
pronounced in HCM vs. control trabeculae (Fig. 2D). The idea that the increase of force in response to 
β-adrenergic stimulation mainly depends on the increase of sarcolemmal Ca2+-entry is in apparent 
contrast with the commonly accepted idea that the positive inotropic effects of β-stimulus stem from 
the increase of sarcoplasmic reticulum Ca2+ content (Desantiago et al., 2008), due to enhancement of 
SERCA function by PKA-mediated phospholamban phosphorylation. The observed acceleration of 
Ca-transient decay under Iso in HCM cardiomyocytes (Fig.4 and Table 2) suggests that the β-
adrenergic-induced increase of SERCA function is preserved in HCM myocardium. The increase of 
SR Ca2+ content following β-stimulation may be limited by the increased diastolic leakage from 
hyper-phosphorylated ryanodine receptors (due to increased Calmodulin-kinase activity, see Coppini 
et al., 2013 and Ferrantini et al 2016)., thus rendering inotropic responses more dependent on the 
increase of Ca2+ entry through the sarcolemma. Another possible contributor to this phenomenon is 
the reduced density of t-tubules (Orchard et al., 2008).  We performed a preliminary investigation of 
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the density of T-tubules in cells isolated from the 10 HCM patient samples included in the study 
(Supplementary Fig. 7): in all the cells observed, T-tubule density was extremely low, much lower 
than the expected for healthy myocardium (Lyon et al., 2009). The functional consequences of β-
adrenergic activation may be radically different in disease myocytes with a markedly reduced density 
of T-tubules. In the near-absence of t-tubules and with a large redistribution of L-Type Ca2+-channels 
to the surface sarcolemma (Coppini et al., 2013), modulation of myocardial inotropism becomes 
largely dependent on the amplitude of Ca2+ trigger (Ferrantini et al., 2014), that is, the density and 
duration of ICaL plus the rate of NCX-mediated Ca2+ entry (reverse mode). Due to the reduced density 
of t-tubules in HCM cardiomyocytes, the prolongation of APs is likely to be essential for the positive-
inotropic effect of β-adrenergic activation.  All in all, the abnormal Ca2+ response to β-stimulus may 
contribute to impair relaxation during exercise, leading to exercise intolerance and exertional 
symptoms in HCM patients, regardless of obstruction.  
 
3) Effects of INaL-inhibitors on APs under β-adrenergic stimulation. 
The abnormal response of HCM myocardium to β-stimulation in terms of AP duration and 
Ca2+ handling underlies the unexpected negative inotropic action of INaL-inhibitors. We found that 
both ranolazine and GS-967, when applied on top of Iso, cause shortening of AP and Ca2+ transient 
duration and reduce Ca2+ transient amplitude (Fig. 4). On the contrary, AP duration does not change in 
response to ranolazine in control cardiomyocytes under Isoproterenol (Supplementary Figure 4). 
Interestingly, AP shortening by INaL-inhibitors occurs also in the absence of β-stimulation (see Figure 
1 for GS-967 and Coppini et al. 2013 for ranolazine). However, when we compare the degree of APD 
shortening by INaL-inhibitors at baseline (in a total of >50 cells combined) with that obtained under Iso 
(in a total of >30 cells), the effect is significantly more pronounced in the presence of β-stimulation: at 
0.5Hz pacing rate, reduction of APD was -27.1±3.7% in the presence of Iso, while it was -17.2±2.4% 
at baseline (P<0.05, linear mixed models). When APD is prolonged and repolarizing K+ currents are 
reduced, the duration of AP plateau is more dependent on INaL (Wu et al., 2011; Shattock et al., 2017): 
therefore, the reduction of APD following a proportionally comparable inhibition of INaL is larger 
when APD is longer and INaL is further increased (i.e. in the presence of isoproterenol). The 
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prolongation of APD in response to isoproterenol leads to an increase in the frequency of early after-
depolarizations (EADs) in HCM cardiomyocytes. Interestingly, when INaL-inhibitors are added on top 
of β-stimulation, the shortening of APD brings the rate of EADs back to baseline, suggesting a 
possible efficacy of INaL-inhibitors in preventing stress-induced arrhythmias in HCM. 
 
4) Effects of INaL-inhibitors on Ca2+-transients and diastolic [Ca2+] under β-adrenergic 
stimulation. 
INaL inhibitors, via shortening of APD, antagonize the increase of the duration of ICaL during 
the plateau of APs induced by Iso in HCM cardiomyocytes, as demonstrated here by AP-Clamp 
experiments (Figure 5 and Supplementary Fig.6), ultimately leading to a marked reduction of total 
Ca2+ entry via ICaL(-65±12% with respect to Iso). This effect is a direct consequence of the shortening 
of APs and does not depend by any direct interactions of INaL inhibitors with Ca2+ channels (Figure 5). 
Moreover, in the presence of β-stimulation, INaL inhibition with ranolazine may reduce intracellular 
[Na+] by a greater extent as compared with the “rest” condition. The marked reduction in intracellular 
[Na+] due to INaL inhibition (Coppini et al., 2013; Kornyeyev et al., 2015) during β-stimulation may 
lead to a pronounced decrease in reverse-mode NCX activity, which in turn may contribute to 
diminish Ca2+ entry during AP plateau. 
In line with the reduction of Ca2+ entry via ICaL and reverse-mode NCX, time-to peak Ca2+-
transients (markedly prolonged by isoproterenol) is brought back to baseline levels by the addition of 
INaL inhibitors (Figure 4 and Table 2). The reduction of isoproterenol-induced AP prolongation by 
INaL-inhibition combined with the decrease of [Na+] may prevent the increase of Ca2+ entry through 
ICaL and reverse-mode NCX contractility by β-stimulation in HCM myocardium. The marked 
reduction of Ca2+ entry appears to be large enough to counteract the isoproterenol-induced increase of 
Ca2+ transient amplitude and force in HCM myocardium, while INaL-inhibitors are unable to 
significantly reduce Ca2+-transient and twitch amplitude in the absence of Iso (Fig.1,3 and 4). In 
parallel with the decrease of reverse-mode NCX, the marked reduction of [Na+] by INaL-inhibition also 
leads to increased forward activity of the exchanger (Coppini et al. 2013), thus increasing the rate of 
Ca2+ efflux through the sarcolemma during the diastolic period. This may have directly contributed to 
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the marked reduction of diastolic [Ca2+] observed when ranolazine or GS-967 are added on top of 
isoproterenol (Fig. 4A-4C). The increased sarcolemmal efflux combined with the decreased Ca2+ 
influx through ICaL is likely to cause a reduction of SR Ca2+ content (Trafford et al., 2001; Eisner et 
al., 2013) in response to INaL-inhibition under Iso. A decrease of SR Ca2+ load may reduce diastolic 
leakage, contributing to the decrease of diastolic cytosolic [Ca2+] (Ferrantini et al., 2016). In line with 
that, the frequency of diastolic Ca2+ waves leading to delayed after-depolarizations (markedly 
increased by isoproterenol) is reduced by INaL-inhibitors in HCM cardiomyocytes under β-stimulation. 
 
The weak β-blocker action of ranolazine is not responsible for its negative inotropic 
effect under isoproterenol. 
Ranolazine was previously shown to behave as a weak β-adrenoceptor blocker (Letienne et 
al., 2001; Flenner et al., 2016), albeit at higher concentrations than that used in our experiments 
(20µM or higher).  We here confirmed that ranolazine mildly binds to β1 and β2 adrenergic receptors 
at the concentration used in our experiments (10µM); on the contrary, GS-967 does not interact with 
β-receptors, even at high concentrations (Supplementary Figure 5). The mild β-blocking effect of 
ranolazine is unlikely to play a major role in the observed response of HCM muscle to ranolazine 
under Iso, for the following reasons: (I)The acceleration of relaxation by Iso is not antagonized by 
10µM ranolazine, only the increase in force amplitude is reduced. (II) The same negative inotropic 
effect as ranolazine is observed with 0.5µM GS-967 (Fig 3E), which does not have any β-blocking 
capabilities (Supplementary Figure 5), in line with previous observations in different healthy and 
diseased animal models (Belardinelli et al., 2013; Fernandes et al., 2014; Alves Bento et al., 2015). 
(III) Finally, when we mimicked the inotropic and lusitropic response to β-stimulation with forskolin 
in HCM trabeculae (thereby bypassing β-receptors), ranolazine, added on top of forskolin, exerted the 
same negative inotropic effect that was observed in the presence of β-stimulation with isoproterenol 
(Supplementary Figure 4). These observations confirm that the interaction of INaL inhibitors with the 
physiological consequences of β-stimulation occurs downstream of the β-receptor and of adenylyl 
cyclase activation and is a sole consequence of the inhibition of INaL.  
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Clinical Implications and conclusions 
In HCM myocardium, disopyramide exerts a potent negative inotropic effect at rest but is less 
effective under β-adrenergic stimulation (Figure 3). This provides a clear explanation of why 
disopyramide effectively reduces resting gradients but is inadequate to control symptoms in patients 
with inducible obstruction. Conversely, INaL-inhibitors (ranolazine and GS-967) reduce myocardial 
force only during β-adrenergic stimulation, used here to simulate exercise and stress. Thanks to this 
effect, ranolazine and selective INaL inhibitors(Justo et al., 2016; Rajamani et al., 2016) may be 
effective in reducing septal tension during exercise and therefore have a theoretical potential to 
ameliorate symptoms caused by inducible obstruction in HCM. Furthermore, by limiting Ca2+ 
overload during stress, INaL inhibitors may also play a protective role against stress-induced 
arrhythmias25, 26. Intriguingly, both ranolazine and GS-967 abolished the increase in spontaneous 
contractions and triggered activity induced by isoproterenol (Fig. 5 and 6). By acting downstream of 
the receptor, INaL inhibitors only counteract the positive inotropic effect of β-adrenergic stimulation on 
septal tension and do not reduce the lusitropic and the chronotropic effects of norepinephrine, which 
are essential to tolerate exercise. High doses of non-selective β-blockers, such as nadolol, are often 
required to reduce dynamic gradients in patients with exertional symptoms due to inducible 
obstruction (Nistri et al., 2012): a large number of patients do not tolerate such aggressive β-blocker 
treatments and are left with residual symptomatic gradients. In other patients, residual dynamic 
gradients persist even at the maximal target dose of β-blockers (e.g. 80-100 mg/day of nadolol, see 
(Nistri et al., 2012). Based on our results, we can envision the use of INaL inhibitors in addition to β-
blockers in patients with residual obstruction-related symptoms at the maximal tolerated dose of β-
blockers, with the purpose of abolishing the remaining inducible gradients. 
In conclusion, the novel selective INaL-inhibitor GS-967 improved diastolic function and 
reduced the arrhythmogenic potential of HCM myocardium in vitro, matching the effects of 
ranolazine at 20-times lower concentrations. INaL-inhibitors (ranolazine and GS-967) appeared to 
reduce septal contractility at peak exercise without affecting resting performance. These data suggest 
improved efficacy of INaL-inhibitors over disopyramide, and a synergistic action to β-blockers, in 
HCM patients with exercise-induced obstruction.  
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Figure 1: (A) Left: representative I
NaL
 traces from an HCM cardiomyocyte during depolarization to -
20mV in the absence (Basal) or presence of GS-967 (0.5 µmol/L). Right: Average integrals of I
NaL
 
calculated between 50 and 750 ms from the onset of depolarization; Means±SE from 14 HCM myocytes 
(5 patients). (B) Representative superimposed action potentials at baseline (black trace) and in the 
presence of GS-967 0.5µM (red trace), elicited at 0.2 Hz. (C) Action potential duration at 90% of 
repolarization (APD90%) at baseline (black) and in the presence of GS-967 0.5µM (red). Means ± 
standard error from 37 HCM cardiomyocytes from 9 HCM patients. (D) Representative superimposed 
Ca-transients at baseline (black traces) and in the presence of GS-967 0.5µM (red traces), elicited at 0.2 
Hz (left) and 1 Hz (right). (E) Time from peak to 50% decay of Ca-transients (50% Decay) at baseline 
(black) and in the presence of GS-967 0.5µM (red), elicited at 0.2, 0.5 and 1 Hz. (F) Diastolic 
  





) at baseline (black) and in the presence of GS-967 0.5µM (red), 





Ca-transient amplitude (Systolic Ampl.) with the application of GS-967 with respect to baseline in 
HCM cardiomyocytes. (E-G) Means ± standard error from 26 cardiomyocytes from 7 HCM patients. 
(H) Representative superimposed force twitches elicited at 0.5Hz in HCM trabeculae in the absence 
(black trace) and presence (red trace) of GS-967. (J) Time from stimulus to peak of force twitches 
elicited at different frequencies (0.1 to 3 Hz) at baseline (black), in the presence of GS-967 (red) and 
after 10 minutes from drug washout (grey). Means ± standard error from 10 trabeculae from 7 patients. 
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Figure 2: Mechanical and electrical response to β-adrenergic stimulation of HCM myocardium. 
(A) Representative superimposed force twitches elicited at 0.5Hz in control (left) and HCM (right) 
trabeculae in the absence and presence of Isoproterenol 10
-7
M (Iso). (B) Isometric tension during steady 
state stimulation at 0.5 in the absence and presence of Iso in control and HCM trabeculae  (C) Duration 
of force twitches (from stimulus to 90% of relaxation) elicited at 0.5 Hz in the absence and presence of 
Isoproterenol 10
-7
M (D) Percentages of Change in the parameters of twitch kinetics (0.5 Hz) upon 
exposure to Iso in Control (cyan) and HCM (green) trabeculae: time from stimulus to peak contraction 
(peak time) and time from peak to 50% of relaxation (RT50%). (B-D) Means ± standard error from 6 
trabeculae from 5 control patients and 30 trabeculae from 20 HCM patients. (E) Representative 
superimposed action potentials elicited at 0.5 Hz in control (left) and HCM (right) cardiomyocytes, in 
the absence and presence of Iso. (F) Percentages of Change in the parameters of action potential kinetics 
upon exposure to Iso in Control (cyan) and HCM (green) cardiomyocytes: time from stimulus to 50% 
repolarization (APD50%) and time from peak to 90% of repolarization (APD90%)  (F) Means ± 
standard error from 13 cardiomyocytes from 5 control patients and 31 cardiomyocytes from 9 HCM 
patients. #=P<0.05, linear mixed models, unpaired comparisons; *=P<0.05, linear mixed models 
corrected for paired comparisons. 
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Figure 3 (next page): GS-967 and ranolazine reduce contractile force only during adrenergic 
stimulation in HCM myocardium. (A) Representative superimposed force twitches elicited at 1Hz in 
HCM trabeculae in the absence (black trace) and presence (blue trace) of Disopyramide 5µM, at basal 
conditions (left) and in the presence of Isoproterenol 10
-7
M (Iso). (B)  Representative superimposed 
force twitches elicited at 1Hz in HCM trabeculae in the absence (black trace) and presence (blue trace) 
of GS-967 0.5µM, at basal conditions (left) and in the presence of Iso. (C) Amplitude of force twitches 
elicited at 1Hz at baseline (black), in the presence of Disopyramide (blue), ranolazine (magenta), GS-
967 (red) or Propranolol (orange), at basal conditions (left) or in the presence of Iso (right). (D) Duration 
of force twitches (from stimulus to 90% repolarization) elicited at 1Hz at baseline (black), in the 
presence of Disopyramide (blue), ranolazine (magenta), GS-967 (red) or Propranolol (orange), at basal 
conditions (left) or in the presence of Iso (right). (C-D) Means ± standard error from 10 trabeculae from 
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Figure 4: (A) Representative simultaneously recorded Action potentials (above) and Ca-transients 
(below) at baseline (left, black traces), in the presence of Isoproterenol 10
-7
M (Iso, center, green traces) 
and in the presence of Ran 10µM added on top of Iso (right, magenta traces), elicited at 0.5 Hz in a 
HCM cardiomyocyte. (B) Ca-transient amplitude (0.5 Hz) at basal conditions (black), in the presence 
of Iso (green), in the presence of ranolazine 10µM added on top of Iso (Iso + Ran, magenta) or with 





at basal conditions (black), in the presence of Iso (green), in the presence of ranolazine 10µM added on 
top of Iso (magenta) or with GS-967 added on top of Iso (red), during regular stimulation at 0.2, 0.5 
and 1Hz (steady state). (D) Action potential duration at 90% repolarization (0.5 Hz) at baseline (black), 
with Iso (green), with Iso + Ran (magenta) or with Iso + GS (red). (B-D) Means ± standard error from 
21 cardiomyocytes from 7 HCM patients. *=P<0.05, linear mixed models, corrected for paired data. 
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Figure5: Ranolazine and GS967 reduce total Ca
2+
 entry through L-Type Ca
2+
 -current under β-
adrenergic stimulation. (A) Representative superimposed L-Type Ca-current traces at baseline (black 
trace) and in the presence of GS-967 0.5µM (red trace) from a HCM cardiomyocyte (the pre-pulse at -
40mV is omitted from the traces). (B) L-Type Ca-current density at baseline (black), in the presence of 
GS-967 0.5µM (red) or 10µM ranolazine(magenta). Means ± standard error from 15 HCM 
cardiomyocytes from 5 patients. (C) Representative superimposed L-Type Ca-current traces at baseline 
(black traces) and in the presence of Iso (green) (D) L-Type Ca-current inactivation time-constant(left) 
and density (right) at baseline (black) and with Iso (green) in HCM cells (13 myocytes, 5 patients). (E) 
Representative L-type Ca-current traces recorded during AP-clamp at baseline (black), with Iso (green) 
and Iso+Ran (magenta); command voltage is shown below. (F) Integral of Ca-current during AP-clamp. 
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Figure 6: (A) Representative action traces at baseline (black traces), in the presence of Isoproterenol 
10
-7
M (Iso, green trace) and in the presence of GS-967 0.5 µM added on top of Iso (red traces), elicited 
at 1 Hz pacing rate. Ranolazine suppresses early after-depolarizations (marked by black arrows) that 
occur under Isoproterenol (B) Representative action potential traces at baseline, with Iso and Iso+Ran, 
0.5Hz pacing rate. Ranolazine suppresses delayed after-depolarizations (marked by black arrows) that 
occur under Isoproterenol. (C-D) Percentage of HCM cardiomyocytes  showing at least 2 early after-
depolarizations (EADs, in C) or 2 delayed after-depolarizations (DADs, in D) during 3 minutes of 
continuous stimulation, at baseline (black), in the presence of Isoprotenerol (Iso), when ranolazine is 
added on top of Iso (magenta) and in the presence of GS-967 0.5µM added on top of Iso (red).  Means 
± standard error from 31 HCM cardiomyocytes from 9 HCM patients. *=P<0.05, linear mixed models 
corrected for paired comparisons. 
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Figure 7: (A) Representative force traces at baseline (black traces), in the presence of Isoproterenol 10
-
7
M (Iso, green trace) and in the presence of Ranolazine 10 µM added on top of Iso (magenta traces), 
elicited at 0.5 Hz pacing rate. Ranolazine suppresses the spontaneous activity that occur under 
Isoproterenol (B) Representative force traces at baseline (black traces), in the presence of Isoproterenol 
10
-7
M (Iso, green trace) and in the presence of Ranolazine 10 µM added on top of Iso (red traces). After 
10 second of burst pacing at 3 Hz, the stimulation was abruptly interrupted to induce spontaneous 
activity. (C) Means ± standard error from 15 HCM trabeculae from 12 HCM patients. *=P<0.05, linear 
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Table 1: Clinical features of the HCM patients enrolled in the study. Clinical data refers to visits 
performed less than 1 month before the myectomy operation. Categorical data is expressed as proportion 
of patients; continuous values are expressed as mean ± standard deviation. NYHA= New York Heart 
HCM Patients (n=22) 
Age at surgery 51 ± 8 yrs 
Gender Female 11/22 (50%) 
NYHA Class II 13/22 (59%) 
NYHA Class III 9/22 (41%) 
Genotype 15/21 (7 MYBPC, 4 MYH,                   
4 SARCOMERE-NEG.) 
Arrhythmic risk 
Syncope 7/22 (32%) 
Non-sustained ventric. tachycardia 11/22 (50%) 
History of Atrial Fibrillation 10/22(45%) 
ICD implanted 3/22 (13%) 
Echo features 
Maximal septal thickness 27±6 mm 
Ejection fraction 66 ± 6 % 
LVOT grad. at rest >30mmHg 22/22 (100%) 
LVOT gradient at rest 81 ± 9 mmHg 
LA end-systolic volume 101 ± 37 mL 




Beta blockers 22/22 (100%) 
Disopyramide 11/22 (50%) 
Amiodarone 4/22 (18%) 
Diuretics/ACE-Inhibitors 11/22 (50%) 
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Association; MYPBC= Myosin-Binding Protein C; MYH= Myosin Heavy Chain; ICD= Implantable 
Cardioverter Defibrillator; LVOT= Left-Ventricular Outflow Tract; LA= Left Atrium.  
  
  
This article is protected by copyright. All rights reserved. 
Table 2: Effects of ranolazine and GS-967 on action 





Table 2: Effects of ranolazine and GS-967 on action potentials and intracellular Ca
2+ 
in the 
presence of Isoproterenol. Data are expressed as means ± standard error of mean. *: data from 25 
HCM cardiomyocytes isolated from 7 HCM patient samples; #: 13 cells, 6 pts.; ‡=12 cells, 5 pts.   P 
values were calculated using linear mixed models corrected for paired comparisons. TTP= time from 
stimulus to peak; 50%= time from peak to 50% decay of Ca-transients; 90%= time from peak to 90% 
decay of Ca-transients; TOT. T.= Total Ca
2+
-transient duration (from stimulus to 95% decay); APD20= 
action potential duration at 20% of repolarization; APD50= action potential duration at 50% of 
repolarization; APD90= action potential duration at 90% of repolarization. 
 
Kinetics 
0.5Hz(ms)                          
 Ca2+ transients         Action Potentials 
TTP 50% 90% TOT. T. APD50 APD90 
Baseline* 163±41 568±54 1010±71 1178±78 699±47 792±50 
Iso 10
-7
M* 315±58 445±58 904±61 1219±79 854±59 981±68 
Iso + Ran
#
 207±29 435±41 903±53 1132±61 706±34 796±40 
Iso + GS
‡
 209±28 432±38 894±56 1128±60 708±32 799±38 
P (Basel. vs 
Iso) 
<0.05 <0.05 <0.05 n.s. <0.05 <0.05 
P (Iso vs 
Iso+Ran) 
<0.05 n.s. n.s. n.s. <0.05 <0.05 
P (Iso vs 
Iso+GS) 
<0.05 n.s. n.s. n.s. <0.05 <0.05 
